Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on IN8bio (INAB – Research Report) and keeping the price target at $6.00.
Swayampakula Ramakanth’s rating is based on several promising developments in IN8bio’s pipeline and financial outlook. The company’s presentation of preclinical data for its INB-600 platform at the AACR meeting highlights its potential to mitigate severe cytokine release syndrome, a significant advantage in treating oncology and autoimmune diseases. This innovation could broaden the platform’s applicability and attract development partners, enhancing its clinical prospects.
Additionally, the upcoming Phase 1 update on INB-200 at the ASCO meeting could further validate its efficacy and safety in treating glioblastoma multiforme, potentially drawing strategic partnerships. Financially, the company reported a net loss in line with expectations and has sufficient cash reserves to fund operations into the second quarter of 2026. These factors, combined with a risk-adjusted net present value analysis, support the Buy rating with a 12-month price target of $6.00 per share.
In another report released on April 28, JonesTrading also maintained a Buy rating on the stock with a $1.20 price target.